Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02733588 · ClinicalTrials.gov registry record · Phase 2
Delivery of G-Pump™ (Glucagon Infusion) From an OmniPod® to Prevent Hypoglycemia in Post-Bariatric Surgery Patients
A Phase 2 study of Hypoglycemia and Complications of Bariatric Procedures, sponsored by Xeris Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
- 1
- Study location
NCT02733588: Completed Phase 2 study of Hypoglycemia and Complications of Bariatric Procedures, sponsored by Xeris Pharmaceuticals.
NCT02733588 is a Phase 2 study of Hypoglycemia and Complications of Bariatric Procedures that has completed, run by Xeris Pharmaceuticals. The registered enrollment target is 8 participants, below the 506-participant average among 40 other Hypoglycemia trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02733588, a Phase 2 study of Hypoglycemia and Complications of Bariatric Procedures, has completed, sponsored by Xeris Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study is to test an optimized control system for sensor-guided (physician administered) delivery of glucagon, and test Proof-of-Concept (POC) in a clinical setting in patients with severe hypoglycemia following bariatric surgery.
Primary Outcome
Frequency with which the device controller software correctly identifies impending hypoglycemia (glucose \< 75 mg/dl) and notifies the investigator to initiate treatment. Reported as the number of successful identifications.
Conditions Studied
Interventions
- DRUG G-Pump™ (glucagon infusion)
Study Locations (1)
Massachusetts
- Joslin Diabetes Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2016-03 |
| Est. Completion | 2017-06-01 |
| Phase | Phase 2 |
What the finished NCT02733588 record still lists
NCT02733588 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 506-participant average among 40 other Hypoglycemia trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Hypoglycemia appearing as the primary indexed condition, and to 1 intervention - of which G-Pump™ (glucagon infusion) is the first listed.
NCT02733588 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02733588 about?
NCT02733588 is a clinical study titled "Delivery of G-Pump™ (Glucagon Infusion) From an OmniPod® to Prevent Hypoglycemia in Post-Bariatric Surgery Patients". The primary objective of this study is to test an optimized control system for sensor-guided (physician administered) delivery of glucagon, and test Proof-of-Concept (POC) in a clinical setting in patients with severe hypoglycemia following bariatric surgery.
What is the current status of trial NCT02733588?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2016-03. Estimated completion is 2017-06-01.
What conditions does trial NCT02733588 study?
This clinical trial studies the following conditions: Hypoglycemia, Complications of Bariatric Procedures.
What interventions are being tested in trial NCT02733588?
The interventions under investigation include: G-Pump™ (glucagon infusion) (DRUG).
Who is sponsoring clinical trial NCT02733588?
This trial is sponsored by Xeris Pharmaceuticals, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02733588 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypoglycemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02733588's enrollment target sits among peer trials
8 37th of 40 higher than 4 of 40 other Hypoglycemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypoglycemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of G-Pen(TM) (Glucagon Injection) to Treat Severe Hypoglycemia
COMPLETED · Phase 2
-
G-Pen™ for Hypoglycemia Rescue in T1D Patients
COMPLETED · Phase 2
-
External Carotid Blood Flow in Individuals With Post-Bariatric Hypoglycemia
RECRUITING
-
A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
RECRUITING · Phase 1
-
Diabetes Clinical Decision Support
RECRUITING · NA
-
Effect of Fasting on Hypoglycemic Counterregulation in Type 1 Diabetes
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia